Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

NCT04409639 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT04409639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04409639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 12, 2021
Completion date
August 31, 2026
Enrollment
14 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia (cmml)